Literature DB >> 1583539

Pharmacophore identification by molecular modeling and chemometrics: the case of HMG-CoA reductase inhibitors.

U Cosentino1, G Moro, D Pitea, S Scolastico, R Todeschini, C Scolastico.   

Abstract

A methodology based on molecular modeling and chemometrics is applied to identify the geometrical pharmacophore and the stereoelectronic requirements for the activity in a series of inhibitors of 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase, an enzyme involved in cholesterol biosynthesis. These inhibitors present two common structural features - a 3,5-dihydroxy hepatanoic acid which mimics the active portion of the natural substrate HMG-CoA and a lipophilic region which carries both polar and bulky groups. A total of 432 minimum energy conformations of 11 homologous compounds showing different levels of biological activity are calculated by the molecular mechanics MM2 method. Five atoms are selected as representatives of the relevant fragments of these compounds and three interatomic distances, selected among 10 by means of a Principal Component Analysis (PCA), are used to describe the three-dimensional disposition of these atoms. A cluster analysis procedure, performed on the whole set of conformations described by these three distances, allows the selection of one cluster whose centroid represents a geometrical model for the HMG-CoA reductase pharmacophore and the conformations included are candidates as binding conformations. To obtain a refinement of the geometrical model and to have a better insight into the requirements for the activity of these inhibitors, the Molecular Electrostatic Potential (MEP) distributions are determined by the MNDO semiempirical method.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1583539     DOI: 10.1007/bf00124386

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  9 in total

1.  Synthesis, biological profile, and quantitative structure-activity relationship of a series of novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

Authors:  S Y Sit; R A Parker; I Motoc; W Han; N Balasubramanian; J D Catt; P J Brown; W E Harte; M D Thompson; J J Wright
Journal:  J Med Chem       Date:  1990-11       Impact factor: 7.446

2.  Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids.

Authors:  G Beck; K Kesseler; E Baader; W Bartmann; A Bergmann; E Granzer; H Jendralla; B von Kerekjarto; R Krause; E Paulus
Journal:  J Med Chem       Date:  1990-01       Impact factor: 7.446

3.  Automatic search for maximum similarity between molecular electrostatic potential distributions.

Authors:  F Manaut; F Sanz; J José; M Milesi
Journal:  J Comput Aided Mol Des       Date:  1991-08       Impact factor: 3.686

4.  3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 1. Structural modification of 5-substituted 3,5-dihydroxypentanoic acids and their lactone derivatives.

Authors:  G E Stokker; W F Hoffman; A W Alberts; E J Cragoe; A A Deana; J L Gilfillan; J W Huff; F C Novello; J D Prugh; R L Smith
Journal:  J Med Chem       Date:  1985-03       Impact factor: 7.446

5.  Inhibitors of cholesterol biosynthesis. 1. trans-6-(2-pyrrol-1-ylethyl)-4-hydroxypyran-2-ones, a novel series of HMG-CoA reductase inhibitors. 1. Effects of structural modifications at the 2- and 5-positions of the pyrrole nucleus.

Authors:  B D Roth; D F Ortwine; M L Hoefle; C D Stratton; D R Sliskovic; M W Wilson; R S Newton
Journal:  J Med Chem       Date:  1990-01       Impact factor: 7.446

6.  A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies.

Authors:  D Mayer; C B Naylor; I Motoc; G R Marshall
Journal:  J Comput Aided Mol Des       Date:  1987-04       Impact factor: 3.686

7.  3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 5. 6-(Fluoren-9-yl)- and 6-(fluoren-9-ylidenyl)-3,5-dihydroxyhexanoic acids and their lactone derivatives.

Authors:  G E Stokker; A W Alberts; J L Gilfillan; J W Huff; R L Smith
Journal:  J Med Chem       Date:  1986-05       Impact factor: 7.446

8.  3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 2. Structural modification of 7-(substituted aryl)-3,5-dihydroxy-6-heptenoic acids and their lactone derivatives.

Authors:  W F Hoffman; A W Alberts; E J Cragoe; A A Deana; B E Evans; J L Gilfillan; N P Gould; J W Huff; F C Novello; J D Prugh
Journal:  J Med Chem       Date:  1986-02       Impact factor: 7.446

9.  3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 3. 7-(3,5-Disubstituted [1,1'-biphenyl]-2-yl)-3,5-dihydroxy-6-heptenoic acids and their lactone derivatives.

Authors:  G E Stokker; A W Alberts; P S Anderson; E J Cragoe; A A Deana; J L Gilfillan; J Hirshfield; W J Holtz; W F Hoffman; J W Huff
Journal:  J Med Chem       Date:  1986-02       Impact factor: 7.446

  9 in total
  1 in total

1.  A 3D QSAR approach to the search for geometrical similarity in a series of nonpeptide angiotensin II receptor antagonists.

Authors:  L Belvisi; G Bravi; C Scolastico; A Vulpetti; A Salimbeni; R Todeschini
Journal:  J Comput Aided Mol Des       Date:  1994-04       Impact factor: 3.686

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.